SELE and plasma cell myeloma: It has been shown that uproleselan offers a promising treatment in preventing metastasis through blocking E-selectin, both in vitro (trans-endothelial migration assay) and in vivo in myeloma, pancreatic and breast cancer models [23,27,57].